← SUPERNUS PHARMACEUTICALS, INC. SUPN
Market Price
$48.27
Market Cap
$2.73B
P/E Ratio
N/A
Revenue (FY 2025)
↑8.6% YoY
$718.95M
3-Yr CAGR: 2.5%
Net Income
↓-152.2% YoY
-$38.55M
Net Margin: -5.4%
Free Cash Flow
↓-73.1% YoY
$45.99M
FCF Yield: 1.68%
EPS (Diluted)
↓-151.5% YoY
$-0.68
Basic: $-0.68
Return on Equity
Efficiency
-3.6%
ROA: -59.0%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (SUPN)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $210.1M | — | $198.1M | $91.2M | — | $1.76 | — | $66.8M | $65.2M | — |
| FY 2017 | $294.1M | +40.0% | $278.9M | $57.3M | -37.2% | $1.08 | -38.6% | $114.6M | $112.6M | +72.7% |
| FY 2018 | $408.9M | +39.0% | $393.5M | $111.0M | +93.8% | $2.05 | +89.8% | $129.0M | $128.1M | +13.8% |
| FY 2019 | $392.8M | -3.9% | $374.5M | $113.1M | +1.9% | $2.10 | +2.4% | $143.1M | $140.4M | +9.6% |
| FY 2020 | $520.4M | +32.5% | $467.9M | $127.0M | +12.3% | $2.36 | +12.4% | $138.4M | $134.9M | -3.9% |
| FY 2021 | $579.8M | +11.4% | $504.7M | $53.4M | -57.9% | $0.98 | -58.5% | $127.1M | $127.1M | -5.8% |
| FY 2022 | $667.2M | +15.1% | $580.0M | $60.7M | +13.6% | $1.04 | +6.1% | $116.8M | $116.4M | -8.4% |
| FY 2023 | $607.5M | -8.9% | $523.7M | $1.3M | -97.8% | $0.02 | -98.1% | $111.1M | $110.5M | -5.1% |
| FY 2024 | $661.8M | +8.9% | $583.9M | $73.9M | +5,512.8% | $1.32 | +6,500.0% | $172.0M | $171.2M | +54.9% |
| FY 2025 | $719.0M | +8.6% | $644.4M | $-38.5M | -152.2% | $-0.68 | -151.5% | $47.3M | $46.0M | -73.1% |
Valuation
Market Price
$48.27
Market Cap
$2.73B
Enterprise Value
N/A
P/E Ratio
N/A
P/B Ratio
2.64
FCF Yield
1.68%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
89.63%
Operating Margin
-8.66%
Net Margin
-5.36%
Return on Equity (ROE)
-3.63%
Return on Assets (ROA)
-59.01%
Asset Turnover
11.01x
Revenue 3-Yr CAGR
2.52%
Financial Health & Liquidity
Current Ratio
0.61
Cash Ratio
1.19
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$128.45M
Total Debt
N/A
Book Value / Share
$18.29
Cash Flow Efficiency
Operating Cash Flow
$47.33M
Capital Expenditures (CapEx)
$1.34M
Free Cash Flow
$45.99M
OCF / Revenue
6.58%
FCF / Revenue
6.40%
FCF 3-Yr CAGR
-26.62%
Per Share Metrics
EPS (Diluted)
$-0.68
EPS (Basic)
$-0.68
Dividends / Share
N/A
Book Value / Share
$18.29
EPS YoY Growth
-151.52%
Balance Sheet (FY 2025)
Total Assets
$65.33M
Total Liabilities
$107.80M
Stockholders' Equity
$1.06B
Current Assets
$65.33M
Current Liabilities
$107.80M